I-MAB
IMAB
Company Profile
Business description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Contact
2440 Research Boulevard
Suite 400
Rockville MD 20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
220
I-MAB News & Analysis
stocks
10 of the cheapest US stocks of 2022
One silver lining of the bear market is half the US stocks followed by Morningstar analysts are now undervalued.
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| All Ordinaries | 8,153.40 | 59.10 | 0.73% |
| CAC 40 | 7,517.68 | 90.66 | 1.22% |
| DAX 40 | 18,417.55 | 118.83 | 0.65% |
| Dow JONES (US) | 40,589.34 | 654.27 | 1.64% |
| FTSE 100 | 8,285.71 | 99.36 | 1.21% |
| HKSE | 17,021.31 | 16.34 | 0.10% |
| NASDAQ | 17,357.88 | 176.16 | 1.03% |
| Nikkei 225 | 37,667.41 | 202.10 | -0.53% |
| NZX 50 Index | 12,349.47 | 46.80 | -0.38% |
| S&P 500 | 5,459.10 | 59.88 | 1.11% |
| S&P/ASX 200 | 7,921.30 | 60.10 | 0.76% |
| SSE Composite Index | 2,890.90 | 4.16 | 0.14% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| Bellevue Gold Ltd BGL | 1.44 | 0.40 | -21.58% |
| Argosy Minerals Ltd AGY | 0.05 | 0.01 | 41.18% |
| Red 5 Ltd RED | 0.38 | 0.02 | -5.06% |
| Pilbara Minerals Ltd PLS | 2.98 | 0.11 | 3.83% |
| Droneshield Ltd DRO | 1.40 | 0.09 | -6.04% |
| Sayona Mining Ltd SYA | 0.03 | 0.00 | 0.00% |
| Core Lithium Ltd CXO | 0.10 | 0.01 | 6.59% |
| Zip Co Ltd ZIP | 1.78 | 0.04 | -1.93% |
| South32 Ltd S32 | 2.98 | 0.07 | 2.41% |
| Telstra Group Ltd TLS | 3.85 | 0.01 | 0.26% |